RxDoctor Payments Data

George Gonzalez, MD

Family Medicine · Clovis, CANPI 1992786487

Payments from drug & device makers

$14,442in general payments, 2019–2025

Across 747 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$2K
  • Amgen$1K
  • Otsuka America Pharmaceutical, Inc.$1K
  • Lilly USA, LLC$838
  • Novo Nordisk$789
  • plus $6K from 52 others

What the payments were for

  • Food & beverage$14,35899%
  • Education$240%
  • Gifts$590%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,442 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$101,869
Medicare patients
162
Services billed
1,618

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide70$79,914
MounjaroTirzepatide55$68,506
JanuviaSitagliptin Phosphate28$38,359
FarxigaDapagliflozin Propanediol21$29,586
EliquisApixaban31$27,071
JardianceEmpagliflozin16$23,393
Breo ElliptaFluticasone/Vilanterol27$12,455
TrintellixVortioxetine Hydrobromide11$7,541
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,015
Lantus SolostarInsulin Glargine,hum.Rec.Anlog57$5,884
Icosapent Ethyl15$5,503
Atorvastatin Calcium333$3,562
BreynaBudesonide/Formoterol Fumarate15$2,208
Levothyroxine Sodium160$2,132
Rosuvastatin Calcium125$2,091

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$789$79,91470 claims
Lilly USA, LLCMounjaro$838$68,50655 claims
MerckJanuvia$226$38,35928 claims
AstraZenecaFarxiga$1,853$29,58621 claims
PfizerEliquis$204$27,07131 claims
Boehringer IngelheimJardiance$104$23,39316 claims
GSKBreo Ellipta, Trelegy Ellipta$467$19,46938 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$771$7,54111 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$125$2,132160 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Clovis

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →